Arcutis Biotherapeutics (ARQT) vs Denali Therapeutics (DNLI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Denali Therapeutics (DNLI) has outperformed Arcutis Biotherapeutics (ARQT) over the past year, gaining 28.6% versus a gain of 17.5%. Over five years, ARQT leads with a +8.5% price change compared with -57.9% for DNLI. Denali Therapeutics is the larger company by market cap ($3.06 billion vs $3.04 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARQT | DNLI |
|---|---|---|
| Share price | $24.17 | $19.16 |
| Market cap | $3.04B | $3.06B |
| 1-day change | +1.05% | -0.62% |
| YTD return | -16.77% | +16.05% |
| 1-year return | +17.50% | +28.59% |
| 5-year return | +8.48% | -57.95% |
| P/E ratio (TTM) | 109.86 | — |
| Forward P/E | 17.77 | — |
| EPS (TTM) | $0.22 | $-2.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $376.07M | $0 |
| Revenue growth (YoY) | +91.34% | — |
| Net income (latest FY) | $-16.14M | $-512.54M |
| Gross margin | 90.24% | — |
| Operating margin | -3.25% | — |
| Net margin | -4.29% | — |
| 52-week high | $31.77 | $27.30 |
| 52-week low | $19.30 | $13.75 |
| Distance from 52-week high | -23.92% | -29.82% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +53.08% | +88.20% |
| Average volume | 2.22M | 1.61M |
| Shares outstanding | 125.69M | 159.85M |
| Employees | 354 | 503 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DNLI has outperformed ARQT by 11.1 percentage points over the past year.
About Arcutis Biotherapeutics
ARQT stock →Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 354 employees
About Denali Therapeutics
DNLI stock →Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 503 employees
ARQT vs DNLI FAQ
Which is bigger, Arcutis Biotherapeutics or Denali Therapeutics?
Denali Therapeutics (DNLI) is larger, with a market capitalization of $3.06B compared with $3.04B for Arcutis Biotherapeutics (ARQT).
Which stock has performed better over the past year, ARQT or DNLI?
DNLI returned +28.59% over the past 12 months, compared with +17.50% for ARQT (price return, excluding dividends). Past performance does not predict future results.
Are Arcutis Biotherapeutics and Denali Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Arcutis Biotherapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for Denali Therapeutics.